Perimenopause Cardiometabolic Risk: Protect Your Heart Early

Most women expect hot flashes and irregular periods in their 40s. Few expect their cholesterol to jump, their blood pressure to creep up, or their waistline to change shape even though nothing about their diet has changed. Yet that is exactly what research shows: perimenopause cardiometabolic risk begins climbing years before your final period, not after it.

Heart disease remains the leading cause of death for women in the United States. In 2020, the American Heart Association (AHA) published its first scientific statement naming the menopause transition as a critical window for prevention (El Khoudary et al., 2020). In other words, the years when your hormones are shifting are also the years when small, targeted changes can have an outsized effect on your long-term heart and metabolic health.

In this article, I’ll walk you through what is happening in your body, which symptoms deserve attention, which labs to ask for, and the evidence-based steps we use at Aya Naturopathic Medicine to help women protect their hearts during this transition.

What Happens During Perimenopause?

Perimenopause is the transition leading up to menopause, which is defined as 12 months without a period. It usually starts in the early-to-mid 40s, though it can begin in the late 30s, and it lasts an average of four to eight years.

During this time, estrogen doesn’t decline in a smooth, gentle slope. It swings, sometimes higher than ever, sometimes very low, while progesterone falls earlier and more steadily. These fluctuations explain the classic symptoms: irregular cycles, hot flashes, night sweats, sleep disruption, anxiety, brain fog, and changes in libido.

What many women aren’t told is that estrogen also acts throughout the cardiovascular and metabolic systems. It helps keep blood vessels flexible, supports healthy cholesterol processing in the liver, and improves how cells respond to insulin. When estrogen becomes erratic and then declines, those protective effects fade.

Why Perimenopause Cardiometabolic Risk Rises

“Cardiometabolic” describes the overlap between heart health and metabolic health: cholesterol, blood sugar, insulin, blood pressure, and body fat distribution. These factors feed into one another, which is why they tend to shift together during midlife. Here is what the research shows.

Cholesterol changes quickly

The Study of Women’s Health Across the Nation (SWAN) followed thousands of women through menopause. It found that LDL cholesterol and apolipoprotein B (the particles that carry cholesterol into artery walls) rose sharply within the year around the final menstrual period, independent of normal aging (Matthews et al., 2009). HDL cholesterol, long considered protective, may also become less effective at this stage (El Khoudary et al., 2020).

Fat moves to the middle

Many women notice that weight shifts to the belly during perimenopause. SWAN data show that fat gain accelerates and lean muscle mass begins to decline during the transition, starting before the final period (Greendale et al., 2019). Visceral (deep abdominal) fat is metabolically active and drives inflammation and insulin resistance. If this sounds familiar, you’re not imagining it, and it isn’t a failure of willpower.

Insulin sensitivity declines

Lower estrogen and a relative increase in androgen activity are linked to higher rates of metabolic syndrome. In SWAN, women whose testosterone-to-SHBG ratio rose during the transition were more likely to develop metabolic syndrome (Janssen et al., 2008). This is one reason perimenopause cardiometabolic risk can show up first as rising fasting glucose or insulin, well before a diabetes diagnosis.

Blood vessels become stiffer

Estrogen supports nitric oxide production, which keeps arteries relaxed. As levels fall, arterial stiffness and blood pressure tend to increase (El Khoudary et al., 2020).

Timing matters

Women who reach menopause early, before age 45, have a higher risk of coronary heart disease and cardiovascular death (Muka et al., 2016). If you’ve had early or surgical menopause, your perimenopause cardiometabolic risk deserves even closer attention.

Your Symptoms May Be Telling You Something About Your Heart

Hot flashes and night sweats are often treated as a nuisance to wait out. Emerging research suggests they may be more meaningful than that. In SWAN, women who had frequent and persistent vasomotor symptoms had a higher risk of later cardiovascular events, including heart attack and stroke (Thurston et al., 2021).

Poor sleep matters too. The AHA now counts sleep as one of eight essential measures of cardiovascular health (Lloyd-Jones et al., 2022), and perimenopause is often when sleep falls apart. Chronic stress, anxiety, and an overactive nervous system add to the burden; if this resonates, our post on HRV biofeedback for anxiety explains one way to help your body recover faster.

None of these symptoms means you have heart disease. They are signals that it’s a good time to look more closely.

Labs and Screening to Ask Your Provider About

A standard annual physical may not catch early changes. When we assess perimenopause cardiometabolic risk, we often look at a broader picture:

These results, combined with your symptoms, family history, and lifestyle, help build a personalized plan rather than a one-size-fits-all approach.

6 Evidence-Based Steps to Lower Your Risk

The good news is that the menopause transition is a window of opportunity. These are the foundations we build on with our patients.

1. Prioritize strength training

Muscle is your most powerful metabolic tissue; it helps clear glucose from the blood and supports healthy body composition. Muscle-strengthening activity is associated with lower risk of cardiovascular disease and death from all causes (Momma et al., 2022). Aim for two to three sessions per week, progressing gradually in load.

2. Eat a Mediterranean-style diet

In the PREDIMED trial, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by about 30% (Estruch et al., 2018). Build meals around vegetables, legumes, whole grains, fish, olive oil, nuts, and seeds. Include protein at each meal to protect muscle, and fiber to support cholesterol and blood sugar.

3. Protect your sleep

Keep a consistent sleep-wake schedule, keep your bedroom cool, and limit alcohol, which worsens both night sweats and sleep quality. If hot flashes are waking you, that’s worth treating, not tolerating.

4. Manage stress and support your nervous system

Chronic stress raises cortisol, blood pressure, and blood sugar. Breathwork, HRV biofeedback, time in nature, and connection with others all help shift the body toward recovery.

5. Support your body’s natural detox and elimination pathways

Your liver processes both hormones and cholesterol, and your gut microbiome influences inflammation and estrogen metabolism. Fiber, hydration, and limiting alcohol help. Learn more in our post on body overload symptoms.

6. Consider targeted, individualized support

Depending on your labs and history, a naturopathic doctor may consider options such as omega-3 fatty acids, soluble fiber (for example, psyllium), or other evidence-informed supplements. These should always be chosen based on your individual needs and checked for interactions with any medications you take.

Where Does Hormone Therapy Fit In?

Menopausal hormone therapy (MHT) is the most effective treatment for hot flashes and night sweats, and our understanding of its safety has evolved significantly since the early Women’s Health Initiative reports. Research now supports a “timing hypothesis”: for healthy women who start MHT within 10 years of menopause or before age 60, the benefits generally outweigh the risks (The North American Menopause Society, 2022). In the ELITE trial, estradiol started early after menopause slowed the progression of carotid artery thickening, while starting it later did not (Hodis et al., 2016).

In November 2025, the U.S. Food and Drug Administration began removing most of the long-standing boxed warning from menopausal hormone therapy labels, citing this updated evidence on timing (U.S. Department of Health and Human Services, 2025). That said, MHT is not currently recommended solely to prevent heart disease, and it isn’t right for everyone. Your personal and family history, blood pressure, clotting risk, and breast health all matter.

The decision is best made with a provider who looks at the whole picture, including your perimenopause cardiometabolic risk. For a deeper look at how hormones affect other systems, read our guide on hormone therapy and bone health.

How Aya Naturopathic Medicine Can Help

At Aya, we see perimenopause as an invitation to get proactive, not a decline to endure. Our approach starts with listening: your symptoms, your history, and your goals. From there, we use comprehensive testing to understand your perimenopause cardiometabolic risk and create a plan that combines nutrition, movement, sleep, stress support, and, when appropriate, hormone therapy or targeted supplements.

Our team includes doctors focused on women’s hormonal health and on cardiometabolic health, including blood sugar, blood pressure, and cholesterol. You can meet the team or browse the conditions we treat. Want to learn in a group setting first? Check our upcoming events for community talks on menopause, muscle, and metabolism.

Your heart health in midlife shapes the decades ahead. Book your visit today or visit our New Patients page to get started.

This article is for educational purposes only and is not a substitute for individualized medical advice. Please talk with your healthcare provider before starting any new treatment or supplement.

References

El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., & Allison, M. A. (2020). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532. https://doi.org/10.1161/CIR.0000000000000912

Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Basora, J., Muñoz, M. A., Sorlí, J. V., Martínez, J. A., Fitó, M., Gea, A., … Martínez-González, M. A. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34. https://doi.org/10.1056/NEJMoa1800389

Greendale, G. A., Sternfeld, B., Huang, M., Han, W., Karvonen-Gutierrez, C., Ruppert, K., Cauley, J. A., Finkelstein, J. S., Jiang, S.-F., & Karlamangla, A. S. (2019). Changes in body composition and weight during the menopause transition. JCI Insight, 4(5), e124865. https://doi.org/10.1172/jci.insight.124865

Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., Stanczyk, F. Z., Selzer, R. H., & Azen, S. P. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241

Janssen, I., Powell, L. H., Crawford, S., Lasley, B., & Sutton-Tyrrell, K. (2008). Menopause and the metabolic syndrome: The Study of Women’s Health Across the Nation. Archives of Internal Medicine, 168(14), 1568–1575. https://doi.org/10.1001/archinte.168.14.1568

Lloyd-Jones, D. M., Allen, N. B., Anderson, C. A. M., Black, T., Brewer, L. C., Foraker, R. E., Grandner, M. A., Lavretsky, H., Perak, A. M., Sharma, G., & Rosamond, W. (2022). Life’s Essential 8: Updating and enhancing the American Heart Association’s construct of cardiovascular health. Circulation, 146(5), e18–e43. https://doi.org/10.1161/CIR.0000000000001078

Matthews, K. A., Crawford, S. L., Chae, C. U., Everson-Rose, S. A., Sowers, M. F., Sternfeld, B., & Sutton-Tyrrell, K. (2009). Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? Journal of the American College of Cardiology, 54(25), 2366–2373. https://doi.org/10.1016/j.jacc.2009.10.009

Momma, H., Kawakami, R., Honda, T., & Sawada, S. S. (2022). Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: A systematic review and meta-analysis of cohort studies. British Journal of Sports Medicine, 56(13), 755–763. https://doi.org/10.1136/bjsports-2021-105061

Muka, T., Oliver-Williams, C., Kunutsor, S., Laven, J. S. E., Fauser, B. C. J. M., Chowdhury, R., Kavousi, M., & Franco, O. H. (2016). Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: A systematic review and meta-analysis. JAMA Cardiology, 1(7), 767–776. https://doi.org/10.1001/jamacardio.2016.2415

The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

Thurston, R. C., Aslanidou Vlachos, H. E., Derby, C. A., Jackson, E. A., Brooks, M. M., Matthews, K. A., Harlow, S., Joffe, H., & El Khoudary, S. R. (2021). Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. Journal of the American Heart Association, 10(3), e017416. https://doi.org/10.1161/JAHA.120.017416

U.S. Department of Health and Human Services. (2025, November 10). Fact sheet: FDA initiates removal of “black box” warnings from menopausal hormone replacement therapy products. https://www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html